Invasiveness of previous treatment for peripheral arterial disease and risk of adverse cardiac events after coronary stenting.

IF 3.1 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Cardiovascular Intervention and Therapeutics Pub Date : 2024-04-01 Epub Date: 2024-02-14 DOI:10.1007/s12928-024-00986-7
Tineke H Pinxterhuis, Clemens von Birgelen, Robert H Geelkerken, Carine J M Doggen, Theo P Menting, K Gert van Houwelingen, Gerard C M Linssen, Eline H Ploumen
{"title":"Invasiveness of previous treatment for peripheral arterial disease and risk of adverse cardiac events after coronary stenting.","authors":"Tineke H Pinxterhuis, Clemens von Birgelen, Robert H Geelkerken, Carine J M Doggen, Theo P Menting, K Gert van Houwelingen, Gerard C M Linssen, Eline H Ploumen","doi":"10.1007/s12928-024-00986-7","DOIUrl":null,"url":null,"abstract":"<p><p>Patients with peripheral arterial disease (PADs), undergoing percutaneous coronary intervention (PCI), have higher adverse event risks. The effect of invasiveness of PADs treatment on PCI outcome is unknown. This study assessed the impact of the invasiveness of previous PADs treatment (invasive or non-invasive) on event risks after PCI with contemporary drug-eluting stents. This post-hoc analysis pooled 3-year patient-level data of PCI all-comer patients living in the eastern Netherlands, previously treated for PADs. PADs included symptomatic atherosclerotic lesion in the lower or upper extremities; carotid or vertebral arteries; mesenteric arteries or aorta. Invasive PADs treatment comprised endarterectomy, bypass surgery, percutaneous transluminal angioplasty, stenting or amputation; non-invasive treatment consisted of medication and participation in exercise programs. Primary endpoint was (coronary) target vessel failure: composite of cardiac mortality, target vessel-related myocardial infarction, or clinically indicated target vessel revascularization. Of 461 PCI patients with PADs, information on PADs treatment was available in 357 (77.4%) patients; 249 (69.7%) were treated invasively and 108 (30.3%) non-invasively. Baseline and PCI procedural characteristics showed no between-group difference. Invasiveness of PADs treatment was not associated with adverse event risks, including target vessel failure (20.5% vs. 16.0%; HR: 1.30, 95%-CI 0.75-2.26, p = 0.35), major adverse cardiac events (23.3% vs. 20.4%; HR: 1.16, 95%-CI 0.71-1.90, p = 0.55), and all-cause mortality (12.1% vs. 8.3%; HR: 1.48, 95%-CI 0.70-3.13, p = 0.30). In PADs patients participating in PCI trials, we found no significant relation between the invasiveness of previous PADs treatment and 3-year outcome after PCI. Consequently, high-risk PCI patients can be identified by consulting medical records, searching for PADs, irrespective of the invasiveness of PADs treatment.</p>","PeriodicalId":9439,"journal":{"name":"Cardiovascular Intervention and Therapeutics","volume":" ","pages":"173-182"},"PeriodicalIF":3.1000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10940370/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular Intervention and Therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s12928-024-00986-7","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/14 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Patients with peripheral arterial disease (PADs), undergoing percutaneous coronary intervention (PCI), have higher adverse event risks. The effect of invasiveness of PADs treatment on PCI outcome is unknown. This study assessed the impact of the invasiveness of previous PADs treatment (invasive or non-invasive) on event risks after PCI with contemporary drug-eluting stents. This post-hoc analysis pooled 3-year patient-level data of PCI all-comer patients living in the eastern Netherlands, previously treated for PADs. PADs included symptomatic atherosclerotic lesion in the lower or upper extremities; carotid or vertebral arteries; mesenteric arteries or aorta. Invasive PADs treatment comprised endarterectomy, bypass surgery, percutaneous transluminal angioplasty, stenting or amputation; non-invasive treatment consisted of medication and participation in exercise programs. Primary endpoint was (coronary) target vessel failure: composite of cardiac mortality, target vessel-related myocardial infarction, or clinically indicated target vessel revascularization. Of 461 PCI patients with PADs, information on PADs treatment was available in 357 (77.4%) patients; 249 (69.7%) were treated invasively and 108 (30.3%) non-invasively. Baseline and PCI procedural characteristics showed no between-group difference. Invasiveness of PADs treatment was not associated with adverse event risks, including target vessel failure (20.5% vs. 16.0%; HR: 1.30, 95%-CI 0.75-2.26, p = 0.35), major adverse cardiac events (23.3% vs. 20.4%; HR: 1.16, 95%-CI 0.71-1.90, p = 0.55), and all-cause mortality (12.1% vs. 8.3%; HR: 1.48, 95%-CI 0.70-3.13, p = 0.30). In PADs patients participating in PCI trials, we found no significant relation between the invasiveness of previous PADs treatment and 3-year outcome after PCI. Consequently, high-risk PCI patients can be identified by consulting medical records, searching for PADs, irrespective of the invasiveness of PADs treatment.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
既往外周动脉疾病治疗的侵袭性与冠状动脉支架置入术后不良心脏事件的风险。
患有外周动脉疾病(PAD)的患者接受经皮冠状动脉介入治疗(PCI)的不良事件风险较高。PADs治疗的侵袭性对PCI结果的影响尚不清楚。本研究评估了既往 PADs 治疗的侵袭性(侵袭性或非侵袭性)对使用当代药物洗脱支架进行 PCI 后的事件风险的影响。这项事后分析汇集了居住在荷兰东部、曾接受过 PADs 治疗的 PCI 全部患者的 3 年患者水平数据。PAD包括下肢或上肢、颈动脉或椎动脉、肠系膜动脉或主动脉的无症状动脉粥样硬化病变。有创动脉粥样硬化治疗包括动脉内膜切除术、搭桥手术、经皮腔内血管成形术、支架植入术或截肢;无创治疗包括药物治疗和参加运动计划。主要终点是(冠状动脉)靶血管衰竭:心脏死亡率、靶血管相关心肌梗死或临床指示的靶血管血运重建的综合结果。在461名患有PAD的PCI患者中,有357名(77.4%)患者获得了PAD治疗信息;249名(69.7%)患者接受了有创治疗,108名(30.3%)患者接受了无创治疗。基线和 PCI 程序特征在组间无差异。无创治疗 PADs 与不良事件风险无关,包括靶血管失败(20.5% 对 16.0%;HR:1.30,95%-CI 0.75-2.26,P = 0.35)、主要不良心脏事件(23.3% vs. 20.4%;HR:1.16,95%-CI 0.71-1.90,p = 0.55)和全因死亡率(12.1% vs. 8.3%;HR:1.48,95%-CI 0.70-3.13,p = 0.30)。在参与 PCI 试验的 PADs 患者中,我们发现既往 PADs 治疗的侵袭性与 PCI 后的 3 年预后之间没有显著关系。因此,无论 PADs 治疗的侵袭性如何,都可以通过查阅病历、搜索 PADs 来识别高风险 PCI 患者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Cardiovascular Intervention and Therapeutics
Cardiovascular Intervention and Therapeutics CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
6.30
自引率
12.50%
发文量
68
期刊介绍: Cardiovascular Intervention and Therapeutics (CVIT) is an international journal covering the field of cardiovascular disease and includes cardiac (coronary and noncoronary) and peripheral interventions and therapeutics. Articles are subject to peer review and complete editorial evaluation prior to any decision regarding acceptability. CVIT is an official journal of The Japanese Association of Cardiovascular Intervention and Therapeutics.
期刊最新文献
3D printing-enhanced transcatheter closure of residual shunts post-ventricular septal perforation: multimodal imaging's crucial role. Physician attending cardiac magnetic resonance imaging for early aortic structural valve deterioration: non-invasive method to identify the regurgitate location. Efficacy of R-N cusp-overlap view as a complementary approach for optimal neocommissural alignment with Navitor valve. Assessment of fractal ratio of vessel diameters in coronary bifurcation lesions by angiography and intravascular ultrasound. Uncrossable aortic stenosis during transcatheter aortic valve replacement: application of balloon-assisted tracking technique.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1